Rick Bienkowski
Stock Analyst at Ladenburg Thalmann & Co.
(0.14)
# 4,610
Out of 4,698 analysts
49
Total ratings
23.5%
Success rate
-21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Initiated Coverage: Buy | $6 | $3.23 | +85.76% | 14 | Aug 18, 2026 | |
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $3 | $1.29 | +132.56% | 2 | Aug 17, 2026 | |
| TTRX Turn Therapeutics | Maintained: Buy | $16 | $9.80 | +63.27% | 1 | Aug 13, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | n/a | $9.40 | - | 1 | Jul 30, 2026 | |
| BEAM Beam Therapeutics | Reiterated: Buy | n/a | $29.66 | n/a | 13 | Aug 19, 2025 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $65 | $12.74 | n/a | 6 | May 29, 2025 | |
| LEGN Legend Biotech | Maintained: Buy | $83 → $55 | $21.52 | n/a | 4 | May 13, 2025 | |
| CRBU Caribou Biosciences | Initiated Coverage: Hold | n/a | $1.57 | n/a | 1 | Nov 8, 2023 | |
| LON: OXB Oxford Biomedica plc | Initiated Coverage: Buy | 840p | 435p | n/a | 1 | May 3, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $112 → $107 | $55.79 | n/a | 6 | Aug 8, 2022 |
Editas Medicine
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $3.23
Upside: +85.76%
PMV Pharmaceuticals
Aug 17, 2026
Reiterated: Buy
Price Target: $3
Current: $1.29
Upside: +132.56%
Turn Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $16
Current: $9.80
Upside: +63.27%
Capricor Therapeutics
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $9.40
Upside: -
Beam Therapeutics
Aug 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $29.66
Upside: n/a
Intellia Therapeutics
May 29, 2025
Reiterated: Buy
Price Target: $65
Current: $12.74
Upside: n/a
Legend Biotech
May 13, 2025
Maintained: Buy
Price Target: $83 → $55
Current: $21.52
Upside: n/a
Caribou Biosciences
Nov 8, 2023
Initiated Coverage: Hold
Price Target: n/a
Current: $1.57
Upside: n/a
Oxford Biomedica plc
May 3, 2023
Initiated Coverage: Buy
Price Target: 840p
Current: 435p
Upside: n/a
CRISPR Therapeutics AG
Aug 8, 2022
Reiterated: Buy
Price Target: $112 → $107
Current: $55.79
Upside: n/a